Our research in coronary artery disease treatments and disorders includes:
- Left main stenting. Director of the Cardiac Catheterization Laboratory Samin K. Sharma, MD, Professor of Cardiology, has pioneered a technique known as "left main stenting" that lowers the risk of complications, requires a shorter hospital stay and offers a speedier recovery than coronary artery bypass surgery.
- Help for those who can’t undergo angioplasty. To help the thousands of patients for whom angioplasty is considered too risky, Mount Sinai Heart has become one of the first centers to use the Impella® 2.5 Circulatory Support System, a ventricular-assist device designed for percutaneous placement in the catheterization lab. The Impella is now becoming the gold standard for high-risk angioplasty cases.
- Drug-eluting stents. The Mount Sinai-led FREEDOM trial (Future REvascularization Evaluation in Patients with Diabetes Mellitus: Optimal management of multivessel disease) is the largest NIH-sponsored trial in history. It compares the efficacy of drug-eluting stents with coronary artery surgery for patients with diabetes, who are at great risk for heart disease.
- Clot-inhibiting treatments. Research conducted by Juan J. Badimon, PhD, Professor of Cardiology, has led to several promising new treatments to inhibit clotting in patients with heart disease. Dr. Badimon and his colleagues have published more than 280 scholarly articles.
- Anti-clotting medications.The Cardiac Catheterization Laboratory, under the direction of Dr. Sharma, has also been a key participant in investigational trials of several anti-clotting medications, including the next-generation anti-platelet medication prasugrel.
- Plaque research. Pedro R. Moreno, MD, Associate Professor of Cardiology, and Dr. Badimon are investigating the mechanisms that trigger the buildup of fatty plaques in the coronary arteries. Halting or even reversing the development of these plaques could result in the development of new therapies to treat CAD.
- Genetics. The Cardiovascular Genetics Program, under the co-direction of Bruce D. Gelb, MD, Professor of Cardiology, works to identify the genetics of heart disease. Finding the genes associated with early risk of CAD means a greater chance of catching the disease before it has progressed to dangerous levels.
- Mobile screenings. Under the leadership of Valentin Fuster, MD, PhD, Professor of Cardiology and Director of Mount Sinai Heart, multi-purpose mobile cardiac imaging units are being deployed to screen approximately 8,000 asymptomatic patients in three U.S. cities. The goal of this project is to discover and develop cost-effective means to identify individuals who have undetected vascular disease and deliver our imaging and diagnostic expertise across large populations at risk.